Evaluation of the pharmacokinetics and bioavailability of intravenously and orally administered amiodarone in horses

American Journal of Veterinary Research

Volumn 67, Issue 3, 2006, Pages 448-454

  De Clercq, Dominique ^a   Baert, Kris ^a   Croubels, Siska ^a   van Loon, Gunther ^a   Maes, An ^a   Tavernier, Rene ^b   Deprez, Piet ^a   De Backer, Patrick ^a  

^a GHENT UNIVERSITY   (Belgium)

^b GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; DEETHYLAMIODARONE; ANTIARRHYTHMIC AGENT;

ANIMAL EXPERIMENT; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG URINE LEVEL; ELECTROCARDIOGRAPHY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; NONHUMAN; PROTEIN BINDING; SINGLE DRUG DOSE; SYMPTOM; URINALYSIS; ANIMAL; AREA UNDER THE CURVE; BIOAVAILABILITY; BLOOD; CLINICAL TRIAL; CROSSOVER PROCEDURE; FEMALE; HORSE; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; RADIOTHERAPY;

ANIMALIA; EQUIDAE;

ADMINISTRATION, ORAL; AMIODARONE; ANIMALS; ANTI-ARRHYTHMIA AGENTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; FEMALE; HEMIBODY IRRADIATION; HORSES; INJECTIONS, INTRAVENOUS;

EID: 33646269795     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.67.3.448     Document Type: Article

References (46)

1. Singh BN. Amiodarone: historical development and pharmacologic profile. Am Heart J 1983;106:788-797.
2. Siddoway LA. Amiodarone: guidelines for use and monitoring. Am Fam Physician 2003;68:2189-2196.
3. Pollak PT, Shafer SL. Use of population modeling to define rational monitoring of amiodarone hepatic effects. Clin Pharmacol Ther 2004;75:342-351.
4. Gill J, Heel RC, Fitton A. Amiodarone. An overview of its pharmacological properties, and review of its therapeutic use in cardiac arrhythmias. Drugs 1992;43:69-110.
5. Trachsel D, Tschudi P, Portier CJ, et al. Pharmacokinetics and pharmacodynamic effects of amiodarone in plasma of ponies after single intravenous administration. Toxicol Appl Pharmacol 2004;195:113-125.
6. Tsikouris JP, Cox GD. A review of class III antiarrhythmic agents for atrial fibrillation: maintenance of normal sinus rhythm. Pharmacotherapy 2001;21:1514-1529.
7. Reef VB, Levitan CW, Spencer PA. Factors affecting prognosis and conversion in equine atrial fibrillation. J Vet Intern Med 1988;2:1-6.
8. Stadler P, Deegen E, Kroker K. Echocardiography and therapy of atrial fibrillation in horses [in German]. Dtsch Tierarztl Wochenschr 1994;101:190-194.
9. Muir WW III, Reed SM, McGuirk SM. Treatment of atrial fibrillation in horses by intravenous administration of quinidine. J Am Vet Med Assoc 1990;197:1607-1610.
10. Marr CM, Reef VB, Reimer JM, et al. An echocardiographic study of atrial fibrillation in horsesi before and after conversion to sinus rhythm. J Vet Intern Med 1995;9:336-340.
11. Reef VB, Reimer JM, Spencer PA. Treatment of atrial fibrillation in hoyses: new perspectives. J Vet Intern Med 1995;9:57-67.
12. Reef VB, McGuirk SM. Diseases of the cardiovascular system. Atrial fibrillation. In: Smith BP, ed. Large animal internal medicine. 3th ed. St Louis: Mosby Year Book Inc, 2002;471-474.
13. McGurrin KMJ, Physick-Sheard PW, Kenney DG, et al. Transvenous electrical cardioversion in equine atrial fibrillation: technique and successful treatment of 3 horses. J Vet Intern Med 2003; 17:715-718.
14. Boriani G, Diemberger I, Biffi M, et al. A. Pharmacological cardioversion of atrial fibrillation: current management and treatment options. Drugs 2004;64:2741-2762.
15. van Loon G, Blissitt KJ, Keen JA, et al. Use of intravenous flecainide in horses with naturally-occurring atrial fibrillation. Equine Vet J 2004;36:609-614.
16. De Clercq D, van Loon G, Baert K, et al. Intravenous amiodarone treatment in horses with chronic atrial fibrillation. Equine Vet J 2006;in press.
17. Ohmura H, Nukada T, Mizuno Y, et al. Safe and efficacious dosage of flecainide acetate for treating equine atrial fibrillation. J Vet Med Sci 2000;62:711-715.
18. Commission Decision of 12 August 2002, implementing Council Directive 96/ 23/EC concerning the performance of analytical methods and the interpretation of results, 2002/657/EC. Official Journal of the European Community 2002; L221/8.
19. Yamaoka K, Nakagawa T, Uno T. Application of Akaike's Information Criterion (AIC) in the evaluation of linear pharmacokinetic equations. J Pharmacokinet Biopharm 1978;6:165-175.
20. Gibaldi M, Perrier D. Multicompartment models: three compartment model. In: Gibaldi M, Perier D, eds. Pharmacokinetics. New York: Marcel Dekker Inc, 1975;89-95.
21. Carlson GP. Clinical chemistry tests. In: Smith BP, ed. Large animal internal medicine. 3th ed. St Louis: Mosby Year Book Inc, 2002;389-412.
22. Chow MSS. Intravenous amiodarone: pharmacology, pharmacokinetics, and clinical use. Ann Pharmacother 1996;30:637-643.
23. Hohnloser SH, Meinertz T, Dammbacher T, et al. Electrocardiographic and antiarrhythmic effects of intravenous amiodarone: results of a prospective, placebo-contTolled study. Am Heart J 1991;121:89-95.
24. van Opstal JM, Schoenmakers M, Verduyn SC, et al. Chronic amiodarone evokes no torsades de pointes arrhythmias despite QT lengthening in an animal model of acquired long-QT syndrome. Circulation 2001;104:2722-2727.
25. Wellens HJJ, Brugada P, Abdollah H, et al. A comparison of the electrophysiologic effects of intravenous and oral amiodarone in the same patient. Circulation 1984;69:120-124.
26. Connolly SJ, Latini R, Kates RE. Pharmacodynamics of intravenous amiodarone in the dog. J Cardiovasc Pharmacol 1984;6:531-535.
27. Vardas PE, Kochiadakis GE, Igoumenidis NE, et al. Amiodarone as a first-choice drug for restoring sinus rhythm in patients with atrial fibrillation: a randomized, controlled study. Chest 2000;117:1538-1545.
28. Weiss M. The anomalous pharmacokinetics of amiodarone explained by nonexponential tissue trapping. J Pharmacokinet Biopharm 1999;27:383-396.
29. Pollak PT, Bouillon T, Shafer SL. Population pharmacokinetics of long-term oral amiodarone therapy. Clin Pharmacol Ther 2000;67:642-652.
30. Meng X, Mojaverian P, Doedée M, et al. Bioavailability of amiodarone tablets administered with and without food in healthy subjects. Am J Cardiol 2001;87:432-435.
31. Broekhuysen J, Laurel R, Sion R. Research on the benzofuran series. XXXVII. Comparative study of transit and metabolism of amiodarone in different species of animals and humans [in French]. Arch Int Pharmacodyn Ther 1969;177:340-359.
32. Andreasen F, Agerbaek H, Bjerregaard P, et al. Pharmacokinetics of amiodarone after intravenous and oral administration. Eur J Clin Pharmacol 1981;19:293-299.
33. Haffajee CI, Love JC, Canada AT, et al. Clinical pharmacokinetics and efficacy of amiodarone for refractory tachyarrhythmias. Circulation 1983;67:1347-1355.
34. Canada AT, Lesko LJ, Haffajee CI, et al. Amiodarone for tachyarrhythmias: pharmacology, kinetics, and efficacy. Drug Intell Clin Pharm 1983;17:100-104.
35. Plomp TA, Rossum JM, Robles de Medina EO, et al. Pharmacokinetics and body distribution of amiodarone in man. Drug Res 1984;34:513-520.
36. Holt DW, Tucker GT, Jackson PR, et al. Amiodarone pharmacokinetics. Am Heart J 1983;106:840-847.
37. Riva E, Gerna M, Latini R, et al. Pharmacokinetics of amiodarone in man. J Cardiovasc Pharmacol 1982;4:264-269.
38. Wyss PA, Moor MJ, Bickel MH. Single-dose kinetics of tissue distribution, excretion and metabolism of amiodarone in rats. J Pharmacol Exp Ther 1990;254:502-507.
39. Veronese ME, McLean S, Hendriks R. Plasma protein binding of amiodarone in a patient population: measurement by erythrocyte partitioning and a novel glass-binding method. Br J Clin Pharmacol 1988;26:721-731.
40. Ujhelyi MR, Klamerus KJ, Vadiei K, et al. Disposition of intravenous amiodarone in subjects with normal and impaired renal function. J Clin Pharmacol 1996;36:122-130.
41. Latini R, Tognoni G, Kates RE. Clinical pharmacokinetics of amiodarone. Clin Pharmacokinet 1984;9:136-156.
42. Ha HR, Follath F. Metabolism of antiarrhythmics. Curr Drug Metab 2004;5:543-571.
43. Rao RH, McCready VR, Spathis GS. Iodine kinetic studies during amiodarone treatment. J Clin Endocrinol Metab 1986; 62:563-568.
44. Gonzalez GA, Garcia SMV, La Mata GM, et al. Early-onset acute toxic hepatitis induced by intravenous amiodarone administration [in Spanish]. Gastroenterol Hepatol 2002;25:392-394.
45. Agozzino F, Picca M, Pelosi G. Acute hepatitis complicating intravenous amiodarone treatment. Ital Heart J 2002;3:686-688.
46. Guglielmini C, Diana A, Lightowler C, et al. Atrial fibrillation in the horse: retrospective study on 30 subjects. Ippologia 2003;14:5-14.